Therapeutic approaches to respiratory diseases excluding asthma: Trends from the patent literature 1997 - 2000

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 2, 2001, Pages 307-322

  Norman, P ^a  

^a NONE   (United Kingdom)

Author keywords

Adult respiratory distress syndrome (ARDS)Bronchitis; Chronic obstructive pulmonary disease (COPD); Cystic fibrosis; Emphysma; Pulmonary fibrosis

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BISINDOLYLMALEIMIDE; CELL ADHESION MOLECULE; CELL ADHESION MOLECULE INHIBITOR; CHEMOKINE RECEPTOR CCR2; CILOMILAST; CYSTEINE PROTEINASE INHIBITOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ELASTASE INHIBITOR; GR 213487; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; METALLOPROTEINASE INHIBITOR; METHYLXANTHINE; PROSTAGLANDIN INHIBITOR; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; SALBUTAMOL; SB 332235; SERINE PROTEINASE INHIBITOR; SIBENADET; STEROID; SURFACTANT; TACHYKININ; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZARFILUKAST; ZD 0892;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; LUNG EMPHYSEMA; LUNG FIBROSIS; PATENT; PUBLICATION; RESPIRATORY TRACT DISEASE;

EID: 0035147056     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.2.307     Document Type: Article

References (52)

1. Pulmonary Diseases
2. Therapeutic approaches to the treatment of asthma: 1997 - 2000
3. Therapeutic approaches to the treatment of respiratory diseases excluding asthma; trends from the patent literature 1993-1997
4. COPD, new developments & therapeutic opportunities
5. Chronic obstructive lung disease, new opportunities for drug development
6. Chronic obstructive pulmonary disease, emerging therapies
7. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
8. Novel therapy for COPD
9. 2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues
10. Discovery and development of selective M3 antagonists for clinical use
11. PDE4 inhibitors: Sustained patenting activity as drugs near the market
12. Neurokinin antagonists
13. Neurokinin-3 receptor antagonists
14. Opportunities for novel therapeutic agents acting at chemokine receptors
15. Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate +/- amiloride in normal human adults
16. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group 1996
17. The role of proteinases in the pathogenesis of chronic bronchitis
18. Matrix metalloproteinases; a role in emphysema
19. Emerging roles for cysteine proteases in human biology
20. Proteinase-antiproteinase imbalance in the pathogenesis of emphysema: The role of metalloproteinases in lung damage
21. Short- and long-term results after lung volume reduction surgery
22. A novel structural motif for serine protease inhibitors
23. Inhibitors of human neutrophil elastase as a potential treatment for inflammatory diseases
24. Therapeutic promises of leukocyte elastase and macrophage metalloelastase inhibitors for the treatment of pulmonary emphysema
25. Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents
26. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats
27. Retinoic acid treatment partially rescues failed septation in rats and in mice
28. Can retinoic acid ameliorate the physiologic and morphologic effects of elastase instillation in the rat?
29. Effects of all-trans-retinoic acid in promoting alveolar repair
30. Cystic fibrosis, current population and survival estimates to the year 2000
31. Cystic fibrosis and the salt controversy
32. Update on clinical trials in the treatment of pulmonary disease in patients with cystic fibrosis
33. NHLBI workshop summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present and future
34. Pulmonary fibrosis, pathways are slowly coming into light
35. New treatments for pulmonary fibrosis?
36. Cell adhesion molecules and pulmonary fibrosis
37. Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis
38. Halofuginone: A novel antifibrotic therapy
39. Epidemiology of acute lung injury and ARDS
40. Epidemiological data challenge ARDS/ALI definition
41. Consensus conference definitions for sepsis, septic shock, acute lung injury and acute respiratory distress syndrome: Time for a reevaluation
42. Acute respiratory distress syndrome
43. Adhesion molecules and cellular biomechanical changes in acute lung injury
44. New inhibitors of p38 kinase
45. Regulation of neutrophil activation in acute lung injury
46. Nitric oxide in the lung: Therapeutic and cellular mechanisms of action
47. Ariflo (SB207499), a second generation, oral PDE4 inhibitor, improves quality of life in patients with COPD
48. PDE4 inhibitors 1999